UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): October 24, 2017

Acadia Healthcare Company, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation) 001-35331 (Commission File Number) 45-2492228 (IRS Employer Identification No.)

6100 Tower Circle, Suite 1000 (Address of Principal Executive Offices)

(615) 861-6000 (Registrant's Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On October 24, 2017, Acadia Healthcare Company, Inc. ("Acadia") issued a press release announcing, among other things, Acadia's operating and financial results for the third quarter ended September 30, 2017. The press release is furnished herewith as Exhibit 99 hereto and is incorporated herein by reference.

Item 9.01	Financial Statements and Exhibits.
(d)	Exhibits.
99	Press Release of Acadia Healthcare Company, Inc., dated October 24, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACADIA HEALTHCARE COMPANY, INC.

By: /s/ Christopher L. Howard

Date: October 24, 2017

Christopher L. Howard Executive Vice President and General Counsel

EXHIBIT INDEX

Exhibit	
No.	Description
<u>99</u>	Press Release of Acadia Healthcare Company, Inc., dated October 24, 2017

Acadia Healthcare Reports Third Quarter Financial Results

Produces U.S. Same Facility Revenue Growth of 6.3%

Revises 2017 Financial Guidance

FRANKLIN, Tenn.--(BUSINESS WIRE)--October 24, 2017--Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the third quarter and nine months ended September 30, 2017. Revenue for the quarter was \$716.7 million, a 2.4% decrease from \$734.7 million for the third quarter of 2016. Net income attributable to Acadia stockholders was \$45.6 million, or \$0.52 per diluted share, for the third quarter of 2017 compared with a net loss attributable to Acadia stockholders of \$117.8 million, or \$1.36 per diluted share, for the third quarter of 2016. Adjusted income from continuing operations attributable to Acadia stockholders per diluted share ("adjusted EPS") was \$0.58 for the third quarter of 2017 compared with \$0.58 for the third quarter of 2016, excluding the impact of transaction-related expenses of \$5.7 million and \$1.1 million for the third quarter of 2017 and 2016, as well as debt extinguishment costs of \$3.4 million and loss on divestiture of \$174.7 million for the third quarter of 2016. A reconciliation of all non-GAAP financial results in this release appears beginning on page 8.

The results for the third quarter were impacted by the divestiture of 22 facilities in the U.K. that occurred on November 30, 2016. On a pro forma basis, adjusting results for the U.K. divestitures, the decrease in the exchange rate and discontinued operations, Acadia's revenue for the third quarter of 2017 increased 4.8% to \$716.7 million compared with \$684.2 million for the third quarter of 2016. Pro forma revenue adjustments for the third quarter of 2016 included a negative impact from the U.K. divestitures of \$45.4 million, \$4.1 million for the discontinued operations, and \$1.0 million from the decline in the exchange rate. Acadia's pro forma adjusted EPS for the third quarter of 2017 increased 18.4% to \$0.58, compared with \$0.49 for the third quarter of 2016. Pro forma adjusted EPS for the third quarter of 2016 included the negative impact from the U.K. divestitures of \$0.09.

Joey Jacobs, Chairman and Chief Executive Officer of Acadia, commented, "For the third quarter of 2017, we continued to be pleased with the performance of our U.S. operations, although we experienced a negative impact from Hurricanes Irma and Maria in Florida, Georgia, and Puerto Rico, which reduced the quarter's earnings by approximately \$0.02 per diluted share. The hurricanes had unfavorable impacts of 60 basis points on same facility revenue and 30 basis points on same facility patient days. Despite this impact, same facility revenue for the U.S. increased 6.3%, with a 4.2% increase in patient days and 2.0% increase in revenue per patient day. U.S. same facility EBITDA margin increased 50 basis points to 26.8% for third quarter of 2017.

"The third quarter financial results for our operations in the United Kingdom reflected a lower census and higher operating costs than anticipated. After experiencing expected seasonal softness in census for the month of August, the typical rebound in census in the month of September was significantly weaker than anticipated. In addition, due to further tightening in the labor market primarily for nurses and other clinical staff, we incurred higher agency labor expense than planned. Same facility revenue increased 3.8% for the quarter, with a 2.5% increase in patient days and a 1.2% increase in revenue per patient day. U.K. same facility EBITDA margin was 21.4% for the quarter compared with 22.6% for the third quarter last year. Total facility EBITDA margin in the U.K. declined 170 basis points to 19.3% for the third quarter of 2017.

"On a consolidated basis, total same facility revenue increased 5.5% for the third quarter, with a 3.5% increase in patient days and a 1.9% increase in revenue per patient day. Total same facility EBITDA margin was 24.9% for the third quarter of 2017 compared with 25.0% for the third quarter of 2016. Our same facility revenue growth resulted, in part, from the addition of more than 600 new beds to existing facilities in the 12 months ended September 30, 2017. During the third quarter, 179 new beds were added to existing facilities. We continue to expect to add approximately 800 new beds to existing facilities and de novo facilities in 2017."

Acadia's consolidated adjusted EBITDA for the third quarter of 2017 was \$152.3 million, or 21.2% of revenue, compared with \$155.8 million, or 21.2% of revenue, for the third quarter of 2016.

Acadia today adjusted its financial guidance for 2017, consistent with the Company's performance for the first nine months of 2017 and its expectations for the fourth quarter of the year, as follows:

- Revenue for 2017 in a range of \$2.82 billion to \$2.83 billion;
- Adjusted EBITDA for 2017 in a range of \$600 million to \$605 million;
- Adjusted earnings per diluted share for 2017 in a range \$2.23 to \$2.25; and
- An exchange rate of \$1.28 per British Pound Sterling and a tax rate of approximately 25%.

The Company's guidance does not include the impact of any future acquisitions or transaction-related expenses. EBITDA is defined as net income adjusted for net income (loss) attributable to noncontrolling interests, provision for income taxes, net interest expense and depreciation and amortization. Adjusted EBITDA is defined as EBITDA adjusted for equity-based compensation expense, debt extinguishment costs, loss on divestiture, gain on foreign currency derivatives and transaction-related expenses. Adjusted income is defined as net income adjusted for provision for income taxes, debt extinguishment costs, loss on divestiture, gain on foreign currency derivatives and transaction-related expenses. Adjusted income is defined as net income adjusted for provision for income taxes, debt extinguishment costs, loss on divestiture, gain on foreign currency derivatives, transaction-related expenses and income tax provision reflecting tax effect of adjustments attributable to Acadia.

Acadia will hold a conference call to discuss its third quarter financial results at 9:00 a.m. Eastern Time on Wednesday, October 25, 2017. A live webcast of the conference call will be available at <u>www.acadiahealthcare.com</u> in the "Investors" section of the website. The webcast of the conference call will be available through November 7, 2017.

Risk Factors

This news release contains forward-looking statements. Generally, words such as "may," "will," "should," "could," "anticipate," "expect," "intend," "estimate," "plan," "continue," and "believe" or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this news release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties and our future results could differ significantly from those expressed or implied by our forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) potential difficulties operating our business in light of political and economic instability in the U.K. and globally following the referendum in the U.K. on June 23, 2016, in which voters approved an exit from the European Union, or Brexit; (ii) the impact of fluctuations in foreign exchange rates, including the devaluation of the British Pound Sterling (GBP) relative to the U.S. Dollar (USD) following the Brexit vote; (iii) Acadia's ability to complete acquisitions and successfully integrate the operations of acquired facilities, including Priory facilities; (iv) Acadia's ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (v) potential reductions in payments received by Acadia from government and third-party payors; (vi) the occurrence of patient incidents and governmental investigations, which could adversely affect the price of our common stock and result in incremental regulatory burdens; (vii) the risk that Acadia may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; and (viii) potential operating difficulties, labor costs, client preferences, changes in competition and general economic or industry conditions that may prevent Acadia from realizing the expected benefits of its business strategy. These factors and others are more fully described in Acadia's periodic reports and other filings with the SEC.

About Acadia

Acadia is a provider of behavioral healthcare services. At September 30, 2017, Acadia operated a network of 579 behavioral healthcare facilities with approximately 17,400 beds in 39 states, the United Kingdom and Puerto Rico. Acadia provides behavioral health and addiction services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.

Acadia Healthcare Company, Inc. Condensed Consolidated Statements of Operations (Unaudited)

		onths Ended ember 30,		Ended September 30,		
	2017	2016	2017	2016		
	(In thousands, exce	cept per share amounts)			
Revenue before provision for doubtful accounts Provision for doubtful accounts	\$ 728,712 (11,998)	\$ 744,802 (10,137)	\$ 2,143,696 (31,892)	\$ 2,139,039 (31,013)		
Revenue	716,714	734,665	2,111,804	2,108,026		
Salaries, wages and benefits (including equity-based compensation expense of \$4,175, \$7,145, \$19,007 and \$20,989, respectively) Professional fees Supplies Rents and leases Other operating expenses Depreciation and amortization Interest expense, net Debt extinguishment costs Loss on divestiture Gain on foreign currency derivatives Transaction-related expenses Total expenses Income (loss) before income taxes Provision for income taxes Net income (loss)	385,562 53,042 28,652 19,049 82,328 36,442 44,515 - - - - - - - - - - - - - - - - - -	$\begin{array}{r} 408,242\\ 47,687\\ 30,555\\ 19,740\\ 79,748\\ 36,418\\ 48,843\\ 3,411\\ 174,739\\ (15)\\ 1,111\\ \underline{850,479}\\ (115,814)\\ 2,396\\ \hline (118,210)\end{array}$	$\begin{array}{c} 1,145,578\\ 142,772\\ 85,000\\ 57,455\\ 249,161\\ 105,256\\ 130,777\\ 810\\ \hline \\ 18,836\\ \hline 1,935,645\\ \hline 176,159\\ 46,259\\ \hline 129,900\\ \end{array}$	$\begin{array}{c} 1,157,557\\ 137,970\\ 88,449\\ 55,013\\ 230,950\\ 101,145\\ 135,315\\ 3,411\\ 174,739\\ (523)\\ 33,483\\ \hline 2,117,509\\ (9,483)\\ 27,767\\ \hline (37,250) \end{array}$		
Net loss attributable to noncontrolling interests	129	402	306	1,575		
Net income (loss) attributable to Acadia Healthcare Company, Inc.	\$ 45,618	\$ (117,808)	\$ 130,206	\$ (35,675)		
Earnings per share attributable to Acadia Healthcare Company, Inc. stockholders: Basic Diluted	\$ 0.52 \$ 0.52	\$ (1.36) \$ (1.36)	\$ 1.50 \$ 1.50	\$ (0.42) \$ (0.42)		
Weighted-average shares outstanding: Basic Diluted	87,017 87,172	86,618 86,618	86,912 87,038	85,376 85,376		

Acadia Healthcare Company, Inc. Condensed Consolidated Balance Sheets (Unaudited)

	September 30, 2017	December 31, 2016
	(In the	ousands)
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 75,661	\$ 57,063
Accounts receivable, net of allowance for doubtful accounts of \$41,786 and \$38,916, respectively	295,756	263,327
Other current assets	92,407	107,537
Total current assets	463,824	427,927
Property and equipment, net	2,966,215	2,703,695
Goodwill	2,730,362	2,681,188
Intangible assets, net	86,951	83,310
Deferred tax assets - noncurrent	3,689	3,780
Derivative instruments	26,176	73,509
Other assets	65,369	51,317
Total assets	\$ 6,342,586	\$ 6,024,726
LIABILITIES AND EQUITY		
Current liabilities:	A A A A A A A A A A	
Current portion of long-term debt	\$ 34,805	\$ 34,805
Accounts payable	95,105	80,034
Accrued salaries and benefits	99,893	105,068
Other accrued liabilities	111,403	122,958
Total current liabilities	341,206	342,865
Long-term debt	3,234,146	3,253,004
Deferred tax liabilities - noncurrent	81,672	78,520
Other liabilities	179,329	164,859
Total liabilities	3,836,353	3,839,248
Redeemable noncontrolling interests	18,648	17,754
Equity:		
Common stock	870	867
Additional paid-in capital	2,512,951	2,496,288
Accumulated other comprehensive loss	(385,180)	(549,570)
Retained earnings	358,944	220,139
Total equity	2,487,585	2,167,724
Total liabilities and equity	\$ 6,342,586	\$ 6,024,726

Acadia Healthcare Company, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited)

Joint Control Joint Control Operating activities (In thousand) Adjustments for recarcle and income (lass) to at each provided by continuing operating activities: 05.258 01.145 Adjustments for recarcle and income (lass) to at each provided by continuing operating activities: 05.258 01.145 Deprecision and anomatication 19.258 01.145 7.340 7.714 Defrect dinome tax expanse 29.416 25.857 20.416 25.857 Defrect dinome tax expanse 29.416 25.857 19.47, 20.06 3.411 Loss on diversiture - 19.47, 20.06 10.27, 73.13 10.27, 73.13 Charge in operating assets and liabilities, not of effect of acquisitions: - (12.579) 0.00, 79.97 Account exerced liabilities 7.677 3.246 (12.579) 0.00, 79.97 Other anomality containing operating activities 7.677 3.246 (12.61) (52.85) Account exerced liabilities 7.677 3.246 (12.61) (52.85) (12.61) (52.85) Charge and for acquisities and heacquisities 7.711, 22.258, 181 (2			Nine Months Ended Septem		
Operating activities: \$ 129900 \$ (77.20) Adjacence tools (000) on et ash provided by continuing operating activities: 105.256 101.145 Arron traiterion of debt issume costs 7,140 7,140 7,140 Equity-Made destinate costs 2,116 2,117 2,007 2,008 Detrocition and monitation of debt issume costs 2,116 2,017 2,018 2,017 2,018 2,017 2,018 2,017 2,018					
Net measure (loss) \$ 12.9.00 \$ (.7.250) Adjustment o recenile at isome (loss) on et cash provided by continuing operating activities: 105,256 101,145 Depreciation and amontization 19,007 20,080 Amontization of cells saure cools 19,007 20,080 Defrect income at expense 29,416 2,5537 Detre atinguishment costs 810 3,411 Loss on diverting sests and liabilities, net of effect of acquisitions: (0,672 731 Chunge in operating sests and liabilities, net of effect of acquisitions: (28,681) (22,793) Other assets 26,669 (12,379) (24,793) Other assets (26,581) 2,067 (23,973) Other assets (26,581) 2,057 (24,973) Other assets (23,271) (25,241) (25,241) Net cash provided by continuing operating activities (21,273) (24,975) Other assets (23,271) (23,273) (24,975) Other assets (23,273) (24,975) (24,975) Other assets (23,271) <th></th> <th></th> <th>(</th> <th>(In thousands)</th> <th></th>			((In thousands)	
Adjustnets to reconcile net income (loss) to art each provided by continuing operating activities 105.256 10.145 Depreciation and anomization of deh issuance costs 7.349 7.714 Equity-based compensation expense 2.9416 2.8537 Debr ectinguistiment costs 810 3.341 Loss on divestifuer - 114,237 Other entremy derivatives - 114,237 Other entremy derivatives - 128,681 Other entremy derivatives 226,099 (12,277) Other accounts payable and other accrued liabilities (26,313) 2,2671 Vestam provided by continuing operating activities 271,511 229,671 Net cash provide captifies and benefits (12,01) (25,313) Loss partice derivations (13,327) (71,747,374) Set cash provide derivations (33,257) (71,747,374) Loss partifies accounts dexits acquisitions (33,257)		¢	129 900	s s	(37.250)
Depreciation and amontanion100.226101,145Amontization of debi issame costs7,3407,714Fajity-basic compensation expense19,00720,989Deferred income tax expense29,41622,5357Det extinguishment costs8103,411Loss on divesture-17,439Gain on foreign currency derivatives-16,227Other-10,672731Caccurrent assets26,660(1,143)Other assets(26,881)(12,279)Other assets(26,381)2,067Accounts propulse and therefits(7,337)(10,737)Other assets7,6773,746Accounts propulse and observities(26,381)22,909Accounts propulse and observities(26,381)22,967Accounts propulse and observities(12,279)(10,737)Other assets7,6773,746Accounts propulse and observities(26,381)22,967Accounts propulse and observities(12,371)229,957Investing activities(12,371)(29,941)Accounts propulse and observities(12,371)(29,945)Investing activities(12,371)(29,941)Investing activities(12,371)(29,941)Investing activities(12,371)(29,941)Investing activities(12,371)(29,941)Investing activities(12,371)(29,941)Investing activities(12,371)(29,941)Investing activities(12,371)(29,941		φ	129,900	, ф	(37,230)
Amenutation of debi issuance costs 7,340 7,740 Equiph-Back compression exponse 29,416 25,857 Debit extinguishment costs 810 3,411 Loss on divestiture - 174,739 Other 10,072 731 Other 10,072 731 Other 10,072 731 Other 22,069 (12,739) Other correct assets 22,069 (12,733) Other correct assets 7,677 3,746 Accords stread howed and other accred liabilities 7,677 3,746 Accords stread howed accred liabilities 7,677 3,640			105 256		101 145
Figure has decomposition expense 19,007 20,009 Defined income tax expense 29,416 25,857 Debined income tax expense 810 3,411 Loss on divestitute - (523) Other 0,6672 731 Change in operating assets and liabilities, net of effect of acquisitions: - (52,697) Accounts payable and other accrued liabilities (26,697) (12,773) Other current assets (26,631) 2,067 Accounts payable and other accrued liabilities (26,331) 2,067 Accounts payable and other accrued liabilities (27,371) (10,797) Other liabilities 7,277 3,346 Net cash provide outpristing activities 271,2131 226,521 Net cash provide outpristing activities (21,2131) (29,991) State assort and liabilities, net of each acquised (12,41) (23,971) Net cash provide outpristing activities (23,176) (971,903) Ender acquisitions, net of cash acquised (23,176) (971,903) Net cash provide outpristing activities (23,176) (17	1		,		,
Deferred means in segmes 29416 25,857 Debet scingulationent costs 810 3,411 Loss on divestiture . 174,739 Gain on foreign euremedy drivatives . (523) Other . (25,57) Accounts receivable, net . (25,69) Other assets . (25,69) (11,74) Accounts proble and other accrued liabilities . (25,69) (11,74) Accounts proble and other accrued liabilities . (25,69) (11,74) Accounts proble and other accrued liabilities . (25,24) . (25,24) Accounts proble and other accrued liabilities . . (25,24) . (25,24) Accounts provided by continuing operating activities .<					
Debt exinguishment coits 810 3,411 Loss on divestitute - (523) Other 10,672 731 Change in operating assets and liabilities, net of effect of acquisitions: - (523) Other current assets (28,681) (12,573) Other current assets (26,699) (12,573) Other current assets (26,811) 2,067 Accounts payable and other accrued liabilities (26,811) 2,067 Accounts payable and other accrued liabilities (7377) 3,246 Net cash provided by continuin generating activities 271,251 226,181 Net cash provided by operating activities 271,251 226,181 Net cash provide organity activities 271,311 229,657 Investing activities (19,1817) (683,285) Cash paid for coquisitions, net of cash acquired (19,1817) (23,97) Cash paid for coquisitions, net of cash acquired (23,176) (71,97) Cash paid for coquisitions, net of cash acquired (23,176) (797,87) Cash paid for coquisitions, net of cash acquired (23,176)			,		,
Los on divestiture -					,
Gain on foreign currency derivatives			010		
Other 10,672 731 Change in operating assets and labilities, net of effect of acquisitions: (28,681) (12,73) Other current assets (26,693) (12,73) Other assets (26,631) 2,067 Accounds payle and other accrued liabilities (26,531) 2,067 Accounds payle and other accrued liabilities (7,337) (10,739) Other current assets (7,337) (10,739) Other assets (7,237) (10,739) Other assets (7,237) (10,739) Other assets (7,237) (10,739) Statistics: (27,151) 259,657 Investing activities (12,21) (55,24) Cash paid for capital expenditures (13,327) (37,947) Statistics: (23,170) (143,83) Cash paid for capital expenditures (23,170) (148,000) Borrowings on long-term debt - (148,000) Borrowings on long-term debt - (148,389) Paynet of faculty - (148,000) Borrowings on long-term					· · · · ·
Change in operating assets and liabilities.Accounts receivable, net(28,681)(12,579)Other current assets(26,089)(12,979)Other assets(26,381)2,067Accounts payable and other accrued liabilities(26,381)2,067Accounts payable and other accrued liabilities(26,381)2,067Accrued aslaries and benefits(7,937)(11,0759)Other liabilities7,6773,746Net cash provided by containing operating activities(12,261)(5524)Net cash provided by containing operating activities(12,261)(5524)Cash gaid for capital expenditores(12,371)(22,967)Cash gaid for capital expenditores(12,371)(23,970)Cash gaid for capital expenditores(12,371)(23,970)Cash gaid for capital expenditores(12,3710)(971,985)Net cash used in investing activities(23,176)(971,985)Net cash used in investing activities-(148,000)Principal payments on revolving craft facility-(148,000)Principal payments on revolving craft facility-(146,069)Principal payments on revolving craft facility-(146,069)Principal payments on revolving craft facility-(146,069)Principal paymen			10 672	-	. ,
Accounts receivable, net(28,681)(12,573)Other assets(566)(1,134)Accounts payble and other accrued liabilities(26,381)(2,067Accrued salaries and benefits(7,937)(10,739)Other liabilities7,6773,3746Net cash provided by continuing operating activities271,2612265,181Net cash provided by operating activities271,351259,657Investing activities211,351(68,228)Cash paid for acquisitions, net of cash acquired(13,817)(249,961)Cash paid for acquisitions(32,277)(37,947)Stellment of foreign currency derivatives(23,277)(37,947)Net cash used in investing activities(23,276)(71,805)Financing activities(23,176)(71,805)Borrowings on long-term debt-1,480,000Borrowings on long-term debt(23,176)(71,900)Principal payment of abusing activities-(14,609)Borrowings on long-term debt-(1,43,389)Borrowings on long-term debt(27,541)(32,78)Principal payment of abusing activities-(1,43,389)Effect of exchange rate changes on cash7,965(9,469)Net cash used in investing activities27,5613,27,561Effect of exchange rate changes on cash7,965(9,469)Net cash used in investing activities27,5613,27,561Effect of exchange rate changes on cash5,0631,21,353Cash and cash equivalents in equivalents </td <td></td> <td></td> <td>10,072</td> <td></td> <td>/51</td>			10,072		/51
Oher current assets $26,099$ $(12,973)$ Oher assets (566) (1.144) Accounts payable and oher accrued liabilities $(26,381)$ 2.067 Accounts payable and oher accrued liabilities $(7,937)$ $(10,759)$ Other liabilities $7,677$ 3.246 Net cash provided by continuing operating activities (1.261) (5.534) Net cash used in discontinued operating activities (1.261) (5.534) Net cash used in accounting activities (1.261) (5.534) Net cash used in acquisitions, net of cash acquired (1.261) (5.534) Cash paid for capital expenditures $(1.93,817)$ $(2.49,961)$ Cash paid for capital expenditures (3.327) (37.947) Settlement of foreign currency derivatives (3.327) (37.947) Oher (6.602) (1.135) $(23.3,176)$ $(971,805)$ Perment of settle acquisitions, net of her accrued the derivatives $(23.3,176)$ $(971,805)$ Perment of borging credit facility $(1.48,380)$ (3.327) $(3.48,380)$ Payment of abused costs $(25,913)$ (46.669) (1.135) Perment of borging credit facility $(2.5,913)$ $(2.5,913)$ $(2.5,913)$ Principal payments on long-term debt $(2.5,913)$ $(2.5,913)$ $(2.5,913)$ Payment of abused costs (3.278) (7.951) $(2.5,913)$ Payment of abused costs $(2.5,742)$ $(2.5,742)$ $(2.5,742)$ Principal payments on long-term debt $(2.5,742)$ $(2.5,742)$ <td< td=""><td></td><td></td><td>(29.691</td><td>`</td><td>(12,570)</td></td<>			(29.691	`	(12,570)
Other assets (566) $(1,134)$ Accound sparks and benefits $(26,381)$ 2.067 Accrued staines and benefits $(7,937)$ $(10,759)$ Other labilities $272,612$ $265,181$ Net each provided by operating activities $(1,261)$ (5.524) Net each provided by operating activities $(1,261)$ (5.524) Net each provided by operating activities $(1,261)$ (5.524) Net each provided by operating activities $(12,31)$ $(25,957)$ Investing activities $(193,817)$ $(249,961)$ Cash pail for capital expenditures $(193,817)$ $(249,961)$ Cash pail for capital expenditures $(13,297)$ $(37,947)$ Settlement of foreign currency derivatives $(233,176)$ $(11,35)$ Other $(6,662)$ $(1,135)$ $(46,060)$ Principal payment activities $(233,176)$ $(21,150)$ $(21,150)$ Enseming activities $(233,176)$ $(21,150)$ $(45,090)$ Principal payment activities $(233,176)$ $(21,150)$ $(46,060)$ Principal payment activities $(233,176)$ $(21,150)$ $(46,060)$ Principal payment on construct models $(25,178)$ $(23,178)$ $(21,151)$ Principal payment activities $(25,178)$ $(23,178)$ $(21,151)$ Issued a flow acquisitions activities $(25,178)$ $(23,178)$ $(21,151)$ Issue and activities $(23,178)$ $(21,151)$ $(23,278)$ $(23,278)$ Issue activities $(23,278)$ $(23,278)$ $(23$					
Accounts payable and other accrued liabilities $(26,381)$ $(20,67)$ Accounts payable and other accrued liabilities $(7,937)$ $(10,759)$ Other liabilities $7,677$ $3,246$ Net each provided by continuing operating activities $(1,261)$ $(1,261)$ Net each provided by operating activities $(1,261)$ $(5,524)$ Net each provided by operating activities $(1,261)$ $(5,524)$ Investing activities $(1,261)$ $(5,524)$ Cash paid for capital expenditures $(1,323)$ $(249,961)$ Cash paid for capital expenditures $(33,279)$ $(37,947)$ Settlement of foreign currency derivatives $(33,270)$ $(37,947)$ Other $(6,602)$ $(1,135)$ $(233,176)$ $(87,180)$ Net each used in investing activities $(233,176)$ $(971,805)$ Financing activities $(233,176)$ $(1,480,380)$ Payment of assumed debt $(25,913)$ $(46,609)$ Principal payments on long-term debt $(25,913)$ $(46,609)$ Principal payments on long-term debt $(2,5742)$ $(33,278)$ Principal payment of assumed debt $(2,5742)$ $(27,542)$ Principal payment of assumed debt $(2,5742)$ $(23,516)$ Principal payment of assumed debt $(2,576)$ $(2,7542)$ Principal payment of assumed debt $(2,5742)$ $(27,542)$ Principal payment of assumed debt $(2,576)$ $(2,576)$ Principal payment of assumed debt $(2,576)$ $(2,576)$ Principal payment of assumed debt $(2,5$,		
Accrace stall areas and hencefits $(7,937)$ $(10,759)$ Other liabilities 7677 $3,736$ Net cash provided by continuing operating activities $(1,201)$ $(5,524)$ Net cash provided by operating activities $271,151$ $259,657$ Investing activities $271,151$ $259,657$ Investing activities $(1,201)$ $(5,524)$ Investing activities $(1,201)$ $(5,524)$ Investing activities $(193,817)$ $(249,961)$ Cash paid for capital expenditures $(193,817)$ $(249,961)$ Cash paid for capital expenditures $(193,817)$ $(249,961)$ Cash paid for capital expenditures $(133,297)$ $(37,947)$ Other $(6,062)$ $(1,135)$ $(11,35)$ Net cash used in investing activities $(23,176)$ $(971,805)$ Financing activities $(25,913)$ $(46,069)$ $(1,135)$ Borrowings on long-tern debt $(25,913)$ $(46,069)$ Principal payments on long-tern debt $(3,278)$ $(7,917)$ Payment of debt issuance costs $(3,278)$ $(7,917)$ Issuance of comonn stock, net $(3,278)$ $(7,917)$ Comonn stock withheld for minimum statutory taxes, net $(3,278)$ $(7,917)$ Other $(6,062)$ $(1,132)$ $(12,13)$ Net cash pation debt $(2,7,422)$ $(7,38,35)$ Payment of debt issuance of comonn stock, net $(2,7,422)$ $(7,38,35)$ Payment of debt issuance of comonn stock withheld for minimum statutory taxes, net $(3,278)$ $(7,917)$ <td></td> <td></td> <td></td> <td></td> <td></td>					
Other labilities $7,77$ $3,746$ Net cash provided by continuing operating activities $272,612$ $265,181$ Net cash provided by operating activities $271,351$ $259,657$ Investing activities $271,351$ $259,657$ Investing activities $271,351$ $259,657$ Investing activities $271,351$ $259,657$ Investing activities $(193,817)$ $(249,961)$ Cash paid for capital expenditures $(193,817)$ $(249,961)$ Cash paid for capital expenditures $(33,297)$ $(37,947)$ Settlement of foreign currency derivatives $(23,176)$ $(77,947)$ Settlement of foreign currency derivatives $(23,176)$ $(77,947)$ Settlement of foreign currency derivatives $(23,176)$ $(79,947)$ Settlement of foreign currency derivatives $(23,176)$ $(77,947)$ Settlement of foreign currency derivatives $(23,176)$ $(71,155)$ Financing activities $(25,913)$ $(40,609)$ Principal payments on nony-term debt $(25,913)$ $(46,606)$ Principal payments on nony-term debt $(25,913)$ $(40,609)$ Payment of assumed debt $(27,542)$ $(33,489)$ Payment of assumed debt $(27,542)$ $(7,947)$ Common stock, withheld for minimum statutory taxes, net $(27,542)$ $(27,542)$ Common stock withheld for minimum statutory taxes, net $(27,542)$ $(7,947)$ Other $16,490$ $(1,248)$ $(27,542)$ $(7,947)$ Net cash and cash equivalents at end of the period					
Net cash provided by continuing operating activities $272,612$ $276,512$ $265,181$ Net cash provided by operating activities $271,351$ $259,657$ Investing activities: $(1,261)$ $(5,524)$ Cash paid for acquisitions, net of cash acquired $ (683,285)$ Cash paid for capital expenditures $(193,817)$ $(249,961)$ Cash paid for capital expenditures $(33,297)$ $(37,947)$ Vet cash used in investing activities (6.602) (1.135) Net cash used in investing activities $(233,176)$ $(971,805)$ Financing activities: $(233,176)$ $(971,805)$ Borrowings on long-tern debt $ 1,480,000$ Borrowings on long-tern debt $ (1,483,389)$ Borrowings on long-tern debt $ (1,483,389)$ Borrowings on revolving credit facility $ (1,640,000)$ Principal payments on long-tern debt $ (1,483,389)$ Borrowings on revolving credit facility $ (1,483,389)$ Payment of debt issuance costs $ (1,483,389)$ Payment of debt issuance costs $ (1,483,389)$ Payment of debt issuance costs $ (23,78)$ Common stock withheld for minimum statutory taxes, net $(27,542)$ $738,153$ Effect of exchange rate changes on cash $7,965$ $(9,469)$ Net increase in cash and cash equivalents at end of the period $\frac{5}{5}, \frac{5}{5}, \frac{5}{5$. , ,
Net cash used in discontinued operating activities (1.261) (5.524) $271,351$ Net cash provided by operating activities $271,351$ $259,657$ Investing activities: $(133,287)$ $(243,961)$ Cash paid for capital expenditures $(133,287)$ $(243,961)$ Cash paid for capital expenditures $(133,287)$ $(233,297)$ Cash paid for capital expenditures $(33,297)$ $(133,297)$ Cash paid for acquisitions, net of cash acquired $(-233,176)$ $(971,805)$ Net cash used in investing activities $(233,176)$ $(971,805)$ Financing activities: $ 1,480,000$ Borrowings on long-term debt $ (1,66,000)$ Principal payments on novolving credit facility $ (134,389)$ Principal payments on novolving credit facility $ (134,389)$ Payment of debt issuance costs $ (134,389)$ Payment of assumed debt $(25,913)$ $(46,069)$ Regargent of assumed debt $(27,542)$ (3278) Common stock withheld for minimum statutory taxes, net (3278) $(7,917)$ Other 1.649 (1.821) Net cash and cash equivalents $8,598$ $16,536$ Cash and cash equivalents at end of the period 5 5 Cash and cash equivalents at end of the period 5 5 Cash and cash equivalents at end of the period 5 5 Cash and cash equivalents at end of the period 5 5 Cash and cash equivalents at end of the period 5 5 <t< td=""><td></td><td></td><td></td><td></td><td>,</td></t<>					,
Net cash provided by operating activities $271,351$ $259,657$ Investing activities: Cash paid for acquisitions, net of cash acquired- $(683,285)$ Cash paid for capital expenditures $(193,817)$ $(249,961)$ Cash paid for capital expenditures $(33,297)$ $(37,447)$ Settlement of forcing currency derivatives $ 523$ Other (6.062) $(1,135)$ Net cash used in investing activities $(233,176)$ $(971,805)$ Financing activities: Borrowings on long-term debt- $14,80,000$ Principal payments on revolving credit facility- $(1,66,000)$ Principal payments on revolving credit facility- $(1,348,389)$ Payment of assumed debt- $(1,348,389)$ Payment of assumed debt- $(25,913)$ $(46,000)$ Principal payments on revolving credit facility- $(1,348,389)$ Payment of assumed debt- $(27,542)$ Payment of assumed for minimum statutory taxes, net $(27,542)$ $(738,153$			272,612		265,181
Investing activities: Cash paid for acquisitions, net of cash acquired Cash paid for acquisitions, net of cash acquired Cash paid for acquisitions (193,817) (249,961) (233,77) (37,947) (37,947) (247) (33,297) (37,947) (37,947) (133,297) (37,947) (133,270) (231,76)(60,62) (1,135) (1,135)Net cash used in investing activities Borrowings on long-term debt Borrowings on long-term debt Principal payments on long-term debt Borrowings on revolving credit facility Principal payments on long-term debt (2,5913) (46,069) Repayment of assumed debt (3,278) (243,176)(48,069) (45,049) (45,049) (45,049) (45,049) (45,049) (45,049) (1,483,389) Payment of debt issuance costs (3,278) (27,542)(3,278) (7,971) (46,069) (45,748) (3,278) (7,971) (45,049) (1,483,389) Payment of debt issuance costs (3,278) (7,971) (1,480,389) (1,483,381) Payment of debt issuance costs (3,278) (7,971) (1,480,389) (27,542) <td>Net cash used in discontinued operating activities</td> <td></td> <td>(1,261</td> <td>)</td> <td>(5,524)</td>	Net cash used in discontinued operating activities		(1,261)	(5,524)
Cash paid for acquisitions, net of cash acquired-(683, 285)Cash paid for radista expenditures(193, 817)(249, 961)Cash paid for ral estate acquisitions(33, 297)(37, 947)Settlement of foreign currency derivatives-523Other(6, 662)(1, 135)Net cash used in investing activities(233, 176)(971, 805)Financing activities:-1, 480, 000Borrowings on long-term debt-1, 480, 000Principal payments on revolving credit facility-(1, 66, 000)Principal payments on long-term debt-(1, 66, 000)Principal payments on long-term debt-(1, 66, 000)Principal payments on convolving credit facility-(1, 66, 000)Principal payments on convolving credit facility-(1, 66, 000)Principal payments on setolving credit facility-(1, 66, 000)Principal payment of debt-(1, 64, 069)Statame costs-(3, 57, 88)Issuance of common stock, net-685, 097Common stock withheld for minimum statutory taxes, net(2, 27, 542)738, 153Defect of exchange rate changes on cash-(2, 7, 542)Net cash equivalents to beginning of the period552, 7, 751Cash and cash equivalents18, 59816, 536Cash and cash equivalents at beginning of the period552, 7, 751Cash and cash equivalents at beginning of the period552, 7, 561Cash and cash equiva	Net cash provided by operating activities		271,351		259,657
Cash paid for capital expenditures $(193,817)$ $(249,961)$ Cash paid for real estate acquisitions $(33,297)$ $(37,947)$ Settlement of foreign currency derivatives $(6,062)$ $(1,135)$ Net cash used in investing activities $(233,176)$ $(971,805)$ Financing activities: $(233,176)$ $(971,805)$ Borrowings on long-term debt $(233,176)$ $(193,817)$ Borrowings on revolving credit facility $ (1480,000)$ Principal payments on one-term debt $(25,913)$ $(46,069)$ Repayment of assumed debt $ (1348,389)$ Payment of debt issuance costs $ (32,78)$ $(7,917)$ Issuance of common stock, net $ (32,78)$ $(7,917)$ Net cash (used in) provided by financing activities $(27,542)$ $738,153$ Effect of exchange rate changes on cash $7,965$ $(9,469)$ Net increase in cash and cash equivalents at beginning of the period $57,063$ $11,215$ Cash and cash equivalents at beginning of the period $57,063$ $11,215$ S tast acquired, excluding cash $5,75,661$ $5,205,407$ Liabilities assumed $5,75,661$ $5,205,407$ Liabilities assumed $5,205,407$ $(1,605,240)$ Liabilities assumed $ (1,605,240)$ Liabilities assumed $ (21,6822)$	Investing activities:				
Cash pial for real estate acquisitions $(33,297)$ $(37,947)$ Settlement of foreign currency derivativesOther (6.062) $(1,135)$ Net cash used in investing activities $(233,176)$ $(971,805)$ Financing activities: $(233,176)$ $(971,805)$ Borrowings on long-term debt $ 1,480,000$ Borrowings on revolving credit facility $ (166,000)$ Principal payments on long-term debt $ (166,000)$ Principal payments on long-term debt $ (166,000)$ Principal payments on long-term debt $ (13,48,389)$ Repayment of assumed debt $ (13,48,389)$ Payment of debt issuance costs $ (35,748)$ Issuance of common stock, net $ (32,78)$ Common stock withheld for minimum statutory taxes, net $(27,542)$ $7,965$ Other $18,598$ $16,536$ Net cash (used in) provided by financing activities $18,598$ $16,536$ Cash and cash equivalents to beginning of the period $\frac{5}{57,661}$ $\frac{5}{5}$ Cash and cash equivalents at end of the period $\frac{5}{57,661}$ $\frac{5}{5}$ Cash and cash equivalents at end of the period $\frac{5}{5}$ $\frac{5}{5,061}$ Cash and cash equivalents at end of the period $\frac{5}{5,061}$ $\frac{5}{5}$ Cash and cash equivalents at end of the period $\frac{5}{5,061}$ $\frac{5}{5}$ Cash and cash equivalents at end of the period $\frac{5}{5,061}$ $\frac{5}{5}$ Cash and cash equivalents at end of the period $\frac{5}{6}$ $\frac{2,05,407}{1,615,520}$	Cash paid for acquisitions, net of cash acquired		-		(683,285)
Settlement of foreign currency derivatives 1.35 523 Other $(6,062)$ $(1,135)$ Net cash used in investing activities $(233,176)$ $(971,805)$ Financing activities: $(233,176)$ $(971,805)$ Borrowings on long-term debt $ 1,480,000$ Borrowings on revolving credit facility $ (196,000)$ Principal payments on revolving credit facility $ (196,000)$ Principal payments on revolving credit facility $ (196,000)$ Principal payment of assumed debt $ (1,348,389)$ Repayment of assumed debt $ (1,348,389)$ Issuance of common stock, net $ 685,097$ Common stock withheld for minimum statutory taxes, net $(3,278)$ $(7,917)$ Other $(27,542)$ $738,153$ Effect of exchange rate changes on cash $7,965$ $(9,469)$ Net increase in cash and cash equivalents $18,598$ $16,536$ Cash and cash equivalents at beginning of the period 5 $75,661$ 5 Cash and cash equivalents at end of the period 5 $75,661$ 5 Effect of acquisitions: 8 $ 5$ $2,505,407$ Liabilities assumed $ (1,65,240)$ $-$ Liabilities assumed $ (1,65,240)$ $-$ Liabilities assumed $ (1,65,240)$ $-$ Common stock in connection with acquisition $ (2,65,4207)$ Cash and cash equivalents at beginning of the period $ (2,65,420)$ <t< td=""><td>Cash paid for capital expenditures</td><td></td><td>(193,817</td><td>')</td><td>(249,961)</td></t<>	Cash paid for capital expenditures		(193,817	')	(249,961)
Settlement of foreign currency derivatives 1.35 523 Other $(6,062)$ $(1,135)$ Net cash used in investing activities $(233,176)$ $(971,805)$ Financing activities: $(233,176)$ $(971,805)$ Borrowings on long-term debt $ 1,480,000$ Borrowings on revolving credit facility $ (196,000)$ Principal payments on revolving credit facility $ (196,000)$ Principal payments on revolving credit facility $ (196,000)$ Principal payment of assumed debt $ (1,348,389)$ Repayment of assumed debt $ (1,348,389)$ Issuance of common stock, net $ 685,097$ Common stock withheld for minimum statutory taxes, net $(3,278)$ $(7,917)$ Other $(27,542)$ $738,153$ Effect of exchange rate changes on cash $7,965$ $(9,469)$ Net increase in cash and cash equivalents $18,598$ $16,536$ Cash and cash equivalents at beginning of the period 5 $75,661$ 5 Cash and cash equivalents at end of the period 5 $75,661$ 5 Effect of acquisitions: 8 $ 5$ $2,505,407$ Liabilities assumed $ (1,65,240)$ $-$ Liabilities assumed $ (1,65,240)$ $-$ Liabilities assumed $ (1,65,240)$ $-$ Common stock in connection with acquisition $ (2,65,4207)$ Cash and cash equivalents at beginning of the period $ (2,65,420)$ <t< td=""><td>Cash paid for real estate acquisitions</td><td></td><td>(33,297</td><td>Ó</td><td>(37,947)</td></t<>	Cash paid for real estate acquisitions		(33,297	Ó	(37,947)
Other $(6,062)$ $(1,135)$ Net cash used in investing activities $(233,176)$ $(971,805)$ Financing activities:- $1,480,000$ Borrowings on long-term debt- $1,480,000$ Principal payments on revolving credit facility- $(166,000)$ Principal payments on nevolving credit facility- $(166,000)$ Principal payments on long-term debt- $(1548,389)$ Repayment of assumed debt- $(1348,389)$ Payment of debt issuance ocsts- $(35,748)$ Issuance of common stock, net- (3278) Common stock withheld for minimum statutory taxes, net $(3,278)$ $(7,917)$ Other1.649 $(1,821)$ Net cash (used in) provided by financing activities $7,965$ $(9,469)$ Net increase in cash and cash equivalents18,598 $16,536$ Cash and cash equivalents at beginning of the period\$ $57,063$ \$Cash and cash equivalents at end of the period\$\$ $(2,504,07)$ Liabilities assumed\$\$\$\$Issuance of common stock in connection with acquisition $(1,65,240)$ $(1,65,240)$			(00,_,,		
Net cash used in investing activities(233,176)(971,805)Financing activities: Borrowings on long-term debt-1,480,000Borrowings on revolving credit facility-179,000Principal payments on revolving credit facility-(166,000)Principal payments on revolving credit facility-(166,000)Principal payments on long-term debt(25,913)(46,069)Repayment of assumed debt-(1,348,389)Repayment of debt issuance costs-(35,748)Issuance of common stock, net-685,097Common stock withheld for minimum statutory taxes, net(3,278)(7,917)Other1,649(1,821)Net cash (used in) provided by financing activities18,59816,536Effect of exchange rate changes on cash7,965(9,469)Net increase in cash and cash equivalents18,59816,536Cash and cash equivalents at beginning of the period\$7,5661\$Cash and cash equivalents at end of the period\$\$.Assumed\$\$\$\$2,205,407Liabilities assumed\$\$\$\$\$Issuance of common stock in connection with acquisition-(1,616,820)\$(1,616,820)-\$\$\$\$(1,616,820)-\$\$\$\$(1,616,820)-\$\$\$\$(1,616,820)-\$\$\$\$(1,616,820)- <t< td=""><td></td><td></td><td>(6.062</td><td>9</td><td></td></t<>			(6.062	9	
Borrowings on long-term debt- $1,480,000$ Borrowings on revolving credit facility- $179,000$ Principal payments on revolving credit facility- $(166,000)$ Principal payments on long-term debt $(25,913)$ $(46,069)$ Repayment of assumed debt- $(1,348,389)$ Payment of debt issuance costs- $(35,748)$ Issuance of common stock, net- $685,097$ Common stock withheld for minimum statutory taxes, net $(3,278)$ $(7,917)$ Other $1,649$ $(1,821)$ Net cash (used in) provided by financing activities $(27,542)$ $738,153$ Effect of exchange rate changes on cash $7,965$ $(9,469)$ Net increase in cash and cash equivalents $8,598$ $16,536$ Cash and cash equivalents at end of the period $\frac{57,063}{57,063}$ $\frac{$27,751}{57,751}$ Effect of acquisitions: 8 - $$2,505,407$ Liabilities assumed $$$ $$$ $$$ $$2,505,407$ Liabilities assumed- $$2,052,407$ $$2,052,407$ Liabilities assumed $$2,052,407$ Liabilities assumed $$2,052,407$ Liabilities					
Borrowings on long-term debt- $1,480,000$ Borrowings on revolving credit facility- $179,000$ Principal payments on revolving credit facility- $(166,000)$ Principal payments on long-term debt $(25,913)$ $(46,069)$ Repayment of assumed debt- $(1,348,389)$ Payment of debt issuance costs- $(35,748)$ Issuance of common stock, net- $685,097$ Common stock withheld for minimum statutory taxes, net $(3,278)$ $(7,917)$ Other $1,649$ $(1,821)$ Net cash (used in) provided by financing activities $(27,542)$ $738,153$ Effect of exchange rate changes on cash $7,965$ $(9,469)$ Net increase in cash and cash equivalents $8,598$ $16,536$ Cash and cash equivalents at end of the period $\frac{57,063}{57,063}$ $\frac{$27,751}{57,751}$ Effect of acquisitions: 8 - $$2,505,407$ Liabilities assumed $$$ $$$ $$$ $$2,505,407$ Liabilities assumed- $$2,052,407$ $$2,052,407$ Liabilities assumed $$2,052,407$ Liabilities assumed $$2,052,407$ Liabilities	Financing activities:				
Borrowings on revolving credit facility-179,000Principal payments on revolving credit facility-(166,000)Principal payments on long-term debt(25,913)(46,069)Repayment of assumed debt-(1,348,389)Payment of debt issuance costs-(35,748)Issuance of common stock, net-685,097Common stock withheld for minimum statutory taxes, net-685,097Other1,649(1,821)Net cash (used in) provided by financing activities(27,542)738,153Effect of exchange rate changes on cash7,965(9,469)Net increase in cash and cash equivalents18,59816,536Cash and cash equivalents at end of the period575,661\$ 27,751Cash and cash equivalents at end of the period\$ -\$ 2,505,407Liabilities assumed\$ -\$ 2,505,407Issuance of common stock in connection with acquisition-(1,65,240)Issuance of common stock in connection with acquisition-\$ 2,505,407			-		1,480,000
Principal payments on revolving credit facility-(166,000)Principal payments on long-term debt(25,913)(46,069)Repayment of assumed debt-(1348,389)Payment of debt issuance costs-(35,748)Issuance of common stock, net-685,097Common stock withheld for minimum statutory taxes, net(3,278)(7,917)Other1,649(1,821)Net cash (used in) provided by financing activities(27,542)738,153Effect of exchange rate changes on cash7,965(9,469)Net increase in cash and cash equivalents18,59816,536Cash and cash equivalents at beginning of the period\$7,561\$Cash and cash equivalents at end of the period\$7,5661\$27,751S\$2,505,407Liabilities assumed\$-\$2,505,407Issuance of common stock in connection with acquisition-(1,605,240)Issuance of common stock in connection with acquisition-(216,882)			-		, ,
Principal payments on long-term debt $(25,913)$ $(46,069)$ Repayment of assumed debt- $(1,348,389)$ Payment of assumed debt- $(35,748)$ Issuance of common stock, net- $(85,097)$ Common stock withheld for minimum statutory taxes, net $(3,278)$ $(7,917)$ Other1,649 $(1,821)$ Net cash (used in) provided by financing activities $(27,542)$ $738,153$ Effect of exchange rate changes on cash $7,965$ $(9,469)$ Net increase in cash and cash equivalents18,598 $16,536$ Cash and cash equivalents at beginning of the period $$7,063$ $11,215$ Cash and cash equivalents at of the period $$7,063$ $$11,215$ Cash and cash equivalents at equivalents at a deginning of the period $$$7,661$ $$$2,7751$ S- $$$(1,605,240)$ $$$$2,505,407$ Liabilities assumed- $$$(2,605,407)$ $$$$(2,604)$ Issuance of common stock in connection with acquisition- $$$(2,604)$			-		,
Repayment of assumed debt- $(1,348,389)$ Payment of debt issuance costs- $(35,748)$ Issuance of common stock, net- $(85,097)$ Common stock withheld for minimum statutory taxes, net $(3,278)$ $(7,917)$ Other1,649 $(1,821)$ Net cash (used in) provided by financing activities $(27,542)$ $738,153$ Effect of exchange rate changes on cash $7,965$ $(9,469)$ Net increase in cash and cash equivalents $18,598$ $16,536$ Cash and cash equivalents at beginning of the period $57,063$ $11,215$ Cash and cash equivalents at end of the period $$7,965$ $$27,751$ Effect of acquisitions: $$$ - $$$$2,505,407Assets acquired, excluding cash$$ - $$$$2,505,407Liabilities assumed- $$$$2,505,407Issuance of common stock in connection with acquisition- $$$Issuance of common stock in connection with acquisition- $$$Issuance of common stock in connection with acquisition- $$$$			(25.913	a	())
Payment of debt issuance costs- $(35,748)$ Issuance of common stock, net- $685,097$ Common stock withheld for minimum statutory taxes, net $(3,278)$ $(7,917)$ Other1,649 $(1,821)$ Net cash (used in) provided by financing activities $(27,542)$ $738,153$ Effect of exchange rate changes on cash $7,965$ $(9,469)$ Net increase in cash and cash equivalents $18,598$ $16,536$ Cash and cash equivalents at beginning of the period $57,063$ $11,215$ Cash and cash equivalents at end of the period $$7,5661$ $$2,7751$ Effect of acquisitions:Assets acquired, excluding cash $$$$ $$$$ $$$, $2,505,407$ Liabilities assumed $$$$ $$$$ $$$$, $2,505,407$ Issuance of common stock in connection with acquisition $$$$ $$$$$$$$, $2,505,407$			(20,)15		
Issuance of common stock, net- $685,097$ Common stock withheld for minimum statutory taxes, net $(3,278)$ $(7,917)$ Other $1,649$ $(1,821)$ Net cash (used in) provided by financing activities $(27,542)$ $738,153$ Effect of exchange rate changes on cash $7,965$ $(9,469)$ Net increase in cash and cash equivalents $18,598$ $16,536$ Cash and cash equivalents at beginning of the period $57,063$ $11,215$ Cash and cash equivalents at end of the period $$ 7,5661$ $$ 2,7511$ Effect of acquisitions: $$ 3, 75,661$ $$ 2,505,407$ Assets acquired, excluding cash $$ 3, - $ 1,1215$ $$ 3, 2,505,407$ Liabilities assumed $$ 3, - $ 1,1215$ $$ 3, - $ 1,1215$ Issuance of common stock in connection with acquisition $$ 3, - $ 1,1215$ $$ 3,2505,407$ Issuance of common stock in connection with acquisition $$ 3, - $ 1,1215$ $$ 3,2505,407$					
Common stock withheld for minimum statutory taxes, net $(3,278)$ $(7,917)$ Other $1,649$ $(1,821)$ Net cash (used in) provided by financing activities $(27,542)$ $738,153$ Effect of exchange rate changes on cash $7,965$ $(9,469)$ Net increase in cash and cash equivalents $18,598$ $16,536$ Cash and cash equivalents at beginning of the period $57,063$ $11,215$ Cash and cash equivalents at end of the period $$ 75,661$ $$ 27,751$ Effect of acquisitions: $$ - $ 2,505,407$ $$ - $ (1,605,240)$ Assets acquired, excluding cash $- $ (216,882)$ $(216,882)$	•		-		
Other $1,649$ $(1,821)$ Net cash (used in) provided by financing activities $(27,542)$ $738,153$ Effect of exchange rate changes on cash $7,965$ $(9,469)$ Net increase in cash and cash equivalents $18,598$ $16,536$ Cash and cash equivalents at beginning of the period $57,063$ $11,215$ Cash and cash equivalents at end of the period $$75,661$ $$27,751$ Effect of acquisitions: $$$75,661$ $$27,751$ Assets acquired, excluding cash $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$			(2 279		· · · · ·
Net cash (used in) provided by financing activities(27,542)738,153Effect of exchange rate changes on cash7,965(9,469)Net increase in cash and cash equivalents18,59816,536Cash and cash equivalents at beginning of the period57,06311,215Cash and cash equivalents at end of the period\$ 75,661\$ 27,751Effect of acquisitions:\$ -\$27,751Assets acquired, excluding cash\$ -\$ 2,505,407Liabilities assumed-(1,605,240)Issuance of common stock in connection with acquisition-(216,882)					
Effect of exchange rate changes on cash $7,965$ $(9,469)$ Net increase in cash and cash equivalents $18,598$ $16,536$ Cash and cash equivalents at beginning of the period $57,063$ $11,215$ Cash and cash equivalents at end of the period $$75,661$ $$27,751$ Effect of acquisitions: Assets acquired, excluding cash Liabilities assumed $$ - $$2,505,407$ $$ - $$1,605,240$ Issuance of common stock in connection with acquisition $- $$2,605,407$ $$$216,882$					
Net increase in cash and cash equivalents $18,598$ $16,536$ Cash and cash equivalents at beginning of the period $57,063$ $11,215$ Cash and cash equivalents at end of the period $$ 75,661$ $$ 27,751$ Effect of acquisitions: Assets acquired, excluding cash $$ - $ 2,505,407$ Liabilities assumed- (1,605,240)Issuance of common stock in connection with acquisition- (216,882)	Net cash (used in) provided by financing activities		(27,542	.)	/38,153
Cash and cash equivalents at beginning of the period $57,063$ $11,215$ Cash and cash equivalents at end of the period\$ $75,661$ \$ Effect of acquisitions: Assets acquired, excluding cash\$-\$Liabilities assumed-(1,605,240)Issuance of common stock in connection with acquisition-(216,882)	Effect of exchange rate changes on cash		7,965	<u> </u>	(9,469)
Cash and cash equivalents at beginning of the period $57,063$ $11,215$ Cash and cash equivalents at end of the period\$ $75,661$ \$ Effect of acquisitions: Assets acquired, excluding cash\$-\$Liabilities assumed-(1,605,240)Issuance of common stock in connection with acquisition-(216,882)	Net increase in cash and cash equivalents		18.598		16.536
Cash and cash equivalents at end of the period\$75,661\$27,751\$-\$-\$27,751Effect of acquisitions: Assets acquired, excluding cash\$-\$\$Liabilities assumed-\$2,505,407Issuance of common stock in connection with acquisition-(1,605,240)Issuance of common stock in connection with acquisition-(216,882)			,		,
Effect of acquisitions:Assets acquired, excluding cash\$-\$2,505,407Liabilities assumed-(1,605,240)Issuance of common stock in connection with acquisition-(216,882)		\$,
Effect of acquisitions: - \$ 2,505,407 Assets acquired, excluding cash - \$ 2,505,407 Liabilities assumed - (1,605,240) Issuance of common stock in connection with acquisition - (216,882)	cash and cash equivalents at the of the period	\$	75,001		27,751
Assets acquired, excluding cash\$-\$2,505,407Liabilities assumed-(1,605,240)Issuance of common stock in connection with acquisition-(216,882)	Effect of acquisitions:	4			
Liabilities assumed - (1,605,240) Issuance of common stock in connection with acquisition - (216,882)		\$	-	. s	2 505 407
Issuance of common stock in connection with acquisition - (216,882)		Φ		Ψ	, ,
			-	-	
Cash paid for acquisitions, net of cash acquired $5 - 5 - 683,285$	*	¢			<u> </u>
	Cash pard for acquisitions, net of cash acquired	\$		· 3	083,283

Acadia Healthcare Company, Inc. Operating Statistics (Unaudited, Revenue in thousands)

	Three Months Ended September 30,					Nine Months Ended September 30,						
		2017		2016	% Change		2017		2016	% Change		
Same Facility Results (a,d)												
Revenue	\$	687,275	\$	651,737	5.5%	\$	1,908,696	\$	1,807,202	5.6%		
Patient Days		1,120,243		1,082,542	3.5%		3,069,574		2,949,223	4.1%		
Admissions		40,332		38,465	4.9%		117,317		110,141	6.5%		
Average Length of Stay (b)		27.8		28.1	-1.3%		26.2		26.8	-2.3%		
Revenue per Patient Day	\$	614	\$	602	1.9%	\$	622	\$	613	1.5%		
EBITDA margin		24.9%		25.0%	-10 bps		25.6%		25.9%	-30 bps		
U.S. Same Facility Results (a)												
Revenue	\$	450,922	\$	424,050	6.3%	\$	1,322,503	\$	1,241,252	6.5%		
Patient Days		621,316		595,989	4.2%		1,821,321		1,729,141	5.3%		
Admissions		37,990		36,177	5.0%		111,743		104,857	6.6%		
Average Length of Stay (b)		16.4		16.5	-0.7%		16.3		16.5	-1.2%		
Revenue per Patient Day	\$	726	\$	712	2.0%	\$	726	\$	718	1.2%		
EBITDA margin		26.8%		26.3%	50 bps		27.2%		27.3%	-10 bps		
U.K. Same Facility Results (a,d)												
Revenue	\$	236,353	\$	227,687	3.8%	\$	586,193	\$	565,950	3.6%		
Patient Days		498,927		486,553	2.5%		1,248,253		1,220,082	2.3%		
Admissions		2,342		2,288	2.4%		5,574		5,284	5.5%		
Average Length of Stay (b)		213.0		212.7	0.2%		223.9		230.9	-3.0%		
Revenue per Patient Day	\$	474	\$	468	1.2%	\$	470	\$	464	1.2%		
EBITDA margin		21.4%		22.6%	-120 bps		22.0%		22.6%	-60 bps		
U.S. Facility Results (c)												
Revenue	\$	453,678	\$	427,417	6.1%	\$	1,355,315	\$	1,256,965	7.8%		
Patient Days	Ŷ	621,648	Ψ	596,717	4.2%	Ψ	1,853,159	Ψ	1,732,252	7.0%		
Admissions		38,034		36,346	4.6%		114,515		105,621	8.4%		
Average Length of Stay (b)		16.3		16.4	-0.4%		16.2		16.4	-1.3%		
Revenue per Patient Day	\$	730	\$	716	1.9%	\$	731	\$	726	0.8%		
EBITDA margin	Ť	26.2%		25.5%	70 bps	*	26.5%		26.6%	-10 bps		
U.K. Facility Results (c,d)												
Revenue	\$	263,036	\$	256,795	2.4%	\$	756,489	\$	656,448	15.2%		
Patient Days		692,509		692,716	0.0%		2,048,424		1,784,618	14.8%		
Admissions		2,622		2,618	0.2%		7,668		6,459	18.7%		
Average Length of Stay (b)		264.1		264.6	-0.2%		267.1		276.3	-3.3%		
Revenue per Patient Day	\$	380	\$	371	2.5%	\$	369	\$	368	0.4%		
EBITDA margin		19.3%		21.0%	-170 bps		19.4%		20.9%	-150 bps		
Total Facility Results (c,d)												
Revenue	\$	716,714	\$	684,212	4.8%	\$	2,111,804	\$	1,913,413	10.4%		
Patient Days		1,314,157		1,289,433	1.9%		3,901,583		3,516,870	10.9%		
Admissions		40,656		38,964	4.3%		122,183		112,080	9.0%		
Average Length of Stay (b)		32.3		33.1	-2.3%		31.9		31.4	1.8%		
Revenue per Patient Day	\$	545	\$	531	2.8%	\$	541	\$	544	-0.5%		
EBITDA margin		23.6%		23.8%	-20 bps		24.0%		24.7%	-70 bps		

(a) Same-facility results for the periods presented exclude the 22 divested facilities in the U.K. that were sold on November 30, 2016, the elderly care division of our U.K. operations and other closed services.

(b) Average length of stay is defined as patient days divided by admissions.

(c) Total Facility results for the periods presented exclude the 22 divested facilities in the U.K. that were sold on November 30, 2016 and other closed services.

(d) Revenue and revenue per patient day for the three and nine months ended September 30, 2016 is adjusted to reflect the foreign currency exchange rate for the comparable period of 2017 in order to eliminate the effect of changes in the exchange rate. The exchange rate used in the adjusted revenue and revenue per patient day amounts for the three and nine months ended September 30, 2016 is 1.309 and 1.275, respectively.

Acadia Healthcare Company, Inc. Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to Adjusted EBITDA (Unaudited)

	Three Months Ended September 30,					Nine Months Ended September 30,				
		2017 2016				2017	2016			
				(in the	ousands)					
Net income (loss) attributable to Acadia Healthcare Company, Inc. Net loss attributable to noncontrolling interests Provision for income taxes Interest expense, net Depreciation and amortization EBITDA	\$	45,618 (129) 15,970 44,515 36,442	\$	(117,808) (402) 2,396 48,843 36,418 (30,553)	\$	130,206 (306) 46,259 130,777 105,256	\$	(35,675) (1,575) 27,767 135,315 101,145 226,977		
Adjustments: Equity-based compensation expense (a) Debt extinguishment costs (b)		4,175		7,145 3,411		412,192 19,007 810		20,989 3,411		
Loss on divestiture (c) Gain on foreign currency derivatives (d) Transaction-related expenses (e) Adjusted EBITDA		5,665		174,739 (15) <u>1,111</u> 155,838		<u>18,836</u> 450,845		174,739 (523) <u>33,483</u> 459,076		
See footnotes on page 10.	¥	102,200	Ψ	100,000			Ψ			

Acadia Healthcare Company, Inc. Reconciliation of Adjusted Income Attributable to Acadia Healthcare Company, Inc. to Net Income Attributable to Acadia Healthcare Company, Inc. (Unaudited)

	Three Months Ended September 30,			Ν	Nine Months Ended September 30,					
	2017		2016		2017			2016		
	(in thousands, except per share amounts)									
Net income (loss) attributable to Acadia Healthcare Company, Inc.	\$	45,618	\$	(117,808)	\$	130,206	\$	(35,675)		
Provision for income taxes		15,970		2,396		46,259		27,767		
Income (loss) attributable to Acadia Healthcare Company, Inc. before income taxes		61,588		(115,412)		176,465		(7,908)		
Adjustments to income:										
Debt extinguishment costs (b)		-		3,411		810		3,411		
Loss on divestiture (c)		-		174,739		-		174,739		
Gain on foreign currency derivatives (d)		-		(15)		-		(523)		
Transaction-related expenses (e)		5,665		1,111		18,836		33,483		
Income tax provision reflecting tax effect of adjustments to income (f)		(17,015)		(13,916)		(48,773)		(44,298)		
Adjusted income attributable to Acadia Healthcare Company, Inc.	\$	50,238	\$	49,918	\$	147,338	\$	158,904		
Weighted-average shares outstanding - diluted (g)		87,172		86,778		87,038		85,643		
Adjusted income attributable to Acadia Healthcare Company, Inc. per diluted share	\$	0.58	\$	0.58	\$	1.69	\$	1.86		

See footnotes on page 10.

Acadia Healthcare Company, Inc. Footnotes

We have included certain financial measures in this press release, including EBITDA, Adjusted EBITDA, and Adjusted income, which are "non-GAAP financial measures" as defined under the rules and regulations promulgated by the SEC. We define EBITDA as net income adjusted for net income (loss) attributable to noncontrolling interests, income tax provision, net interest expense and depreciation and amortization. We define Adjusted EBITDA as EBITDA adjusted for equity-based compensation expense, debt extinguishment costs, loss on divestiture, gain on foreign currency derivatives, transaction-related expenses. We define Adjusted income tax provision reflecting tax effect of adjusted for provision for income taxes, debt extinguishment costs, loss on divestiture, gain on foreign currency derivatives, transaction-related expenses and income tax provision reflecting tax effect of adjustments attributable to Acadia.

EBITDA, Adjusted EBITDA, and Adjusted income are supplemental measures of our performance and are not required by, or presented in accordance with, generally accepted accounting principles in the United States ("GAAP"). EBITDA, Adjusted EBITDA, and Adjusted income are not measures of our financial performance under GAAP and should not be considered as alternatives to net income or any other performance measures derived in accordance with GAAP or as an alternative to cash flow from operating activities as measures of our liquidity. Our measurements of EBITDA, Adjusted EBITDA, and Adjusted income may not be comparable to similarly titled measures of other companies. We have included information concerning EBITDA, Adjusted EBITDA, and Adjusted income in this press release because we believe that such information is used by certain investors as measures of a company's historical performance. We believe these measures are frequently used by securities analysts, investors and other interested parties in the evaluation of issuers of equity securities, many of which present EBITDA, Adjusted EBITDA, and Adjusted income when reporting their results. Our presentation of EBITDA, Adjusted EBITDA, and Adjusted income when reporting their results. Our presentation of EBITDA, adjusted EBITDA, and Adjusted income when reporting their results. Our presentation of EBITDA, adjusted EBITDA, and Adjusted income when reporting their results. Our presentation of EBITDA, adjusted EBITDA, and Adjusted income should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.

The Company is not able to provide a reconciliation of projected Adjusted EBITDA and adjusted earnings per diluted share, where provided, to expected results due to the unknown effect, timing and potential significance of transaction-related expenses and the tax effect of such expenses.

(a) Represents the equity-based compensation expense of Acadia.

(b) For the three and nine months ended September 30, 2017 and 2016, represents debt extinguishment costs recorded in connection with the Amended and Restated Credit Agreement, including the discount and write-off of deferred financing costs.

(c) Loss on divesture in the U.K. includes an allocation of goodwill to the disposal groups of approximately \$106.9 million, loss on the sale of properties of approximately \$42.2 million and transaction-related expenses of approximately \$25.6 million.

(d) Represents the change in fair value of foreign currency derivatives purchased by Acadia related to (i) acquisitions in the U.K. and (ii) transfers of cash between the U.S. and U.K. under the Company's cash management and foreign currency risk management programs.

(e) Represents transaction-related expenses incurred by Acadia related to acquisitions and integration efforts.

(f) Represents the income tax provision adjusted to reflect the tax effect of the adjustments to income based on tax rates of 25.3% and 21.8% for the three months ended September 30, 2017 and 2016, respectively, and 24.9% and 21.8% for the nine months ended September 30, 2017 and 2016, respectively. The adjusted income tax provision for the nine months ended September 30, 2017 excludes the impact of adopting ASU 2016-09 "Improvements to Employee Share-Based Payment Accounting" of approximately \$1.7 million.

(g) For the three and nine months ended September 30, 2016, approximately 0.2 million and 0.3 million, respectively, of the outstanding restricted stock and shares of common stock issuable upon exercise of outstanding stock option awards have been included in the calculation of weighted-average shares outstanding-diluted. These shares are excluded from the calculation of diluted earnings per share in the condensed consolidated statement of operations because the net loss for the three and nine months ended September 30, 2016 causes such securities to be anti-dilutive.

CONTACT: Acadia Healthcare Company, Inc. Gretchen Hommrich, 615-861-6000 Director, Investor Relations